Healthcare Equities Slip as Biotech Deals and FDA Updates Shake Market

The Food and Drug Administration retracted its earlier alert claiming Taylor Farms lettuce tested positive for cyclospora. While the agency continues to investigate products pulled from shelves, the abrupt correction has deepened uncertainty regarding the ongoing foodborne-illness outbreak and public safety protocols.

Corporate activity remained aggressive despite the broader sector dip. Chicago-based Tempus AI moved to consolidate its position in genomics by acquiring the remaining stake in Personalis for $16.25 per share. The transaction, valuing the Fremont-based company at $1.5 billion, offers a 5.6% premium over its previous closing price and bolsters Tempus’s capabilities in minimal residual disease tracking.

Meanwhile, Bristol Myers Squibb deepened its reliance on high-performance computing, announcing an expansion of its partnership with Nvidia. By integrating Nvidia’s DGX Vera Rubin NVL72 systems, the pharmaceutical giant aims to accelerate its AI-driven drug discovery efforts and sharpen computational efficiency across its research stack.